TABLE 1.
Characteristics of patients prescribed posaconazolea
| Characteristicb | DR tablet (n = 20) | Suspension (n = 43) | Pd |
|---|---|---|---|
| Median age (IQR) | 55.5 (46.6–62.9) | 55.8 (43.7–61.4) | 0.802 |
| Male gender | 12 (60.0) | 26 (60.5) | 0.972 |
| Inpatient status at initiation | 10 (50) | 18 (41.9) | 0.545 |
| Possible, probable, or proven IFI at initiation | 9 (45) | 31 (72.1) | 0.038 |
| Regular diet status for >50% of time from initiation to first level | 20 (100) | 41 (95.4) | 0.327 |
| Post-stem cell transplant (allogeneic) | 7 (35) | 14 (32.6) | 0.848 |
| Hematologic malignancy | 13 (65) | 28 (65.1) | 0.993 |
| Acute myeloid leukemia | 8 (40) | 10 (23.3) | |
| Chronic lymphocytic leukemia | 1 (5) | 8 (18.6) | |
| Acute lymphocytic leukemia | 1 (5) | 0 | |
| Chronic myeloid leukemia | 1 (5) | 3 (7) | |
| Lymphoma | 1 (5) | 3 (7) | |
| Multiple myeloma | 0 | 1 (2.3) | |
| Other | 1 (5) | 3 (7) | |
| Solid organ transplant | 4 (20) | 12 (27.9) | 0.502 |
| Lung | 2 (10) | 6 (14) | |
| Liver | 0 | 1 (2.3) | |
| Kidney | 1 (5) | 2 (4.7) | |
| Heart/lung | 0 | 1 (2.3) | |
| Heart/kidney | 0 | 1 (2.3) | |
| Kidney/pancreas | 0 | 1 (2.3) | |
| Liver/lung | 1 (5) | 0 | |
| Acid suppression | 20 (100) | 34 (79.1) | 0.027 |
| PPI | 20 (100) | 29 (67.4) | |
| H2 blocker | 0 | 5 (11.6) | |
| Other interacting medicationsc | 1 (5) | 0 (0) | 0.139 |
| Diarrhea | 3 (15) | 10 (23.3) | 0.451 |
| Mucositis | 2 (10) | 2 (4.7) | 0.418 |
| Gastrointestinal GVHD | 0.716 | ||
| Acute | 2 (10) | 2 (4.7) | |
| Chronic | 1 (5) | 2 (4.7) | |
| Neutropenia | 4 (20) | 11 (25.6) | 0.628 |
| Concomitant use of another antifungal | 7 (35) | 25 (58.1) | 0.087 |
a
Values are numbers and percentages unless otherwise noted.
b
IQR, interquartile range; IFI, invasive fungal infection; GVHD, graft-versus-host disease.
c
The only interacting medication recorded was metoclopramide.
d
P values derived using Pearson's chi-squared test for categorical variables and Wilcoxon rank sum test for continuous variables.